Quinones: coenzyme Q10 (ubidecarenone (INN))

In 2024, quinones: coenzyme q10 (ubidecarenone (inn)) trade exhibited strong growth, with global flows reaching $304,021,881 and a three-year compound annual growth rate of -9.7% (five-year: +13.7%). The all-time peak of $412,535,562 was recorded in 2021; the current level is 26% below that high-water mark.

Over the 30-year observation window (1995–2024), 59% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is decelerating (-14.4% acceleration).

The supply side is concentrated (Herfindahl-Hirschman Index 0.560). The three largest exporters — China ($224.3M), Japan ($35.7M), and Netherlands ($9.2M) — collectively dominate supply flows. The leading exporter has grown at -12.5% over the last three years.

On the demand side, importer concentration is moderately concentrated (HHI 0.212). The three largest import markets are United States ($134.7M), Australia ($17.1M), and Netherlands ($13.9M). The largest importing market sources from 13 different supplying countries.

The dominant trade corridor is China → United States at $126.3M, representing 93.8% of the importer's total demand.

The volatility score for quinones: coenzyme q10 (ubidecarenone (inn)) is 7 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, strong demand tailwinds create a favourable entry environment. The concentrated supply structure suggests high barriers but also potential opportunity if dominant suppliers face disruption or capacity constraints.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.